FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883655238> ?p ?o ?g. }

• W2883655238 abstract "Bisphosphonates are a class of drugs that slow bone loss and are a promising candidate to treat knee osteoarthritis (OA) patients. In a pilot study, we demonstrated that zoledronic acid reduced knee pain and size of subchondral bone marrow lesions (BMLs) over 6 months in knee OA patients with significant knee pain and BMLs. A longer, larger study is required to assess whether decreases in BML size will translate to reductions in cartilage loss over time. We are currently conducting a multicentre, randomised, double-blind, placebo-controlled trial over 24 months that aims to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change (assessed using magnetic resonance imaging (MRI)) and knee pain in knee OA patients.Two hundred sixty-four patients with clinical knee OA, significant knee pain and subchondral BMLs present on MRI will be recruited in Hobart, Melbourne, Sydney and Adelaide. They will be randomly allocated to the two arms of the study, receiving an annual identical intravenous infusion of either 100 mL of fluid containing zoledronic acid (5 mg/100 mL) or placebo (0.9% NaCl 100 mL), at baseline and 1 year later. MRI of the study knee will be performed at screening, month 6 and 24. Knee structure, symptoms and function will be assessed using validated methods. The primary outcome is absolute change in tibiofemoral cartilage volume (mm3) over 24 months. Secondary outcomes include improvement in knee pain over 3, 6, 12, 18, and 24 months and reductions in BML size over 6 and 24 months. The primary analyses will be intention-to-treat analyses of primary and secondary outcomes. Per protocol analyses will be performed as the secondary analyses.This study will provide high-quality evidence to assess whether zoledronic acid has a novel disease modifying effect in OA by slowing cartilage loss and reducing pain. If zoledronic acid proves effective, it suggests great potential for cost savings through a delay or reduced need for joint replacement surgery, and potential for great improvements in quality of life for OA suffers.Australian New Zealand Clinical Trials Registry: ACTRN12613000039785 , registered on 14 January 2013." @default.
• W2883655238 created "2018-08-03" @default.
• W2883655238 creator A5007693688 @default.
• W2883655238 creator A5011312213 @default.
• W2883655238 creator A5013194494 @default.
• W2883655238 creator A5019374074 @default.
• W2883655238 creator A5026779492 @default.
• W2883655238 creator A5029405051 @default.
• W2883655238 creator A5041094807 @default.
• W2883655238 creator A5047388413 @default.
• W2883655238 creator A5056675626 @default.
• W2883655238 creator A5071553641 @default.
• W2883655238 date "2018-07-18" @default.
• W2883655238 modified "2023-09-27" @default.
• W2883655238 title "A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients – ZAP2" @default.
• W2883655238 cites W133618362 @default.
• W2883655238 cites W1526337969 @default.
• W2883655238 cites W1534458869 @default.
• W2883655238 cites W1974759500 @default.
• W2883655238 cites W1993035292 @default.
• W2883655238 cites W1994787220 @default.
• W2883655238 cites W1995629342 @default.
• W2883655238 cites W1997148651 @default.
• W2883655238 cites W1997637714 @default.
• W2883655238 cites W2005381591 @default.
• W2883655238 cites W2013462509 @default.
• W2883655238 cites W2015382881 @default.
• W2883655238 cites W2019026866 @default.
• W2883655238 cites W2020618120 @default.
• W2883655238 cites W2029393328 @default.
• W2883655238 cites W2032306447 @default.
• W2883655238 cites W2033250480 @default.
• W2883655238 cites W2042196436 @default.
• W2883655238 cites W2043338780 @default.
• W2883655238 cites W2052056367 @default.
• W2883655238 cites W2058147305 @default.
• W2883655238 cites W2058641170 @default.
• W2883655238 cites W2064753036 @default.
• W2883655238 cites W2065901234 @default.
• W2883655238 cites W2068043810 @default.
• W2883655238 cites W2077941564 @default.
• W2883655238 cites W2081741530 @default.
• W2883655238 cites W2089704358 @default.
• W2883655238 cites W2096658173 @default.
• W2883655238 cites W2097785638 @default.
• W2883655238 cites W2097950056 @default.
• W2883655238 cites W2103603390 @default.
• W2883655238 cites W2104105208 @default.
• W2883655238 cites W2105539667 @default.
• W2883655238 cites W2108696783 @default.
• W2883655238 cites W2109441608 @default.
• W2883655238 cites W2110705709 @default.
• W2883655238 cites W2110814621 @default.
• W2883655238 cites W2110900487 @default.
• W2883655238 cites W2118903184 @default.
• W2883655238 cites W2119266342 @default.
• W2883655238 cites W2119527637 @default.
• W2883655238 cites W2122833449 @default.
• W2883655238 cites W2122913203 @default.
• W2883655238 cites W2128250249 @default.
• W2883655238 cites W2128831972 @default.
• W2883655238 cites W2129719054 @default.
• W2883655238 cites W2133149338 @default.
• W2883655238 cites W2139049840 @default.
• W2883655238 cites W2140513563 @default.
• W2883655238 cites W2144247138 @default.
• W2883655238 cites W2146002675 @default.
• W2883655238 cites W2148218555 @default.
• W2883655238 cites W2150309582 @default.
• W2883655238 cites W2159624824 @default.
• W2883655238 cites W2162077957 @default.
• W2883655238 cites W2162085535 @default.
• W2883655238 cites W2165689145 @default.
• W2883655238 cites W2167230918 @default.
• W2883655238 cites W2167933345 @default.
• W2883655238 cites W2168342322 @default.
• W2883655238 cites W2172170054 @default.
• W2883655238 cites W2274722622 @default.
• W2883655238 cites W2328300656 @default.
• W2883655238 cites W2763901799 @default.
• W2883655238 cites W2772240823 @default.
• W2883655238 cites W4236805817 @default.
• W2883655238 cites W4255724762 @default.
• W2883655238 cites W4375798889 @default.
• W2883655238 doi "https://doi.org/10.1186/s12891-018-2143-2" @default.
• W2883655238 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6052532" @default.
• W2883655238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30021646" @default.
• W2883655238 hasPublicationYear "2018" @default.
• W2883655238 type Work @default.
• W2883655238 sameAs 2883655238 @default.
• W2883655238 citedByCount "20" @default.
• W2883655238 countsByYear W28836552382019 @default.
• W2883655238 countsByYear W28836552382020 @default.
• W2883655238 countsByYear W28836552382021 @default.
• W2883655238 countsByYear W28836552382022 @default.
• W2883655238 countsByYear W28836552382023 @default.
• W2883655238 crossrefType "journal-article" @default.
• W2883655238 hasAuthorship W2883655238A5007693688 @default.
• W2883655238 hasAuthorship W2883655238A5011312213 @default.
• W2883655238 hasAuthorship W2883655238A5013194494 @default.

• next